Cardiovascular and autoimmune diseases in females: The role of microvasculature and dysfunctional endothelium

Atherosclerosis

Volumn 241, Issue 1, 2014, Pages 259-263

  Gianturco, L ^a   Bodini, B D ^a   Atzeni, F ^a,b   Colombo, C ^a   Stella, D ^a   Sarzi Puttini, P ^b   Drago, L ^c   Galaverna, S ^a   Turiel, M ^a  

^a IRCCS ISTITUTO ORTOPEDICO GALEAZZI   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

Autoimmune diseases; Cardiovascular diseases; Endothelial dysfunction; Females

Indexed keywords

AUTOIMMUNE DISEASE; AUTOIMMUNITY; CARDIOVASCULAR DISEASE; COMORBIDITY; FEMALE; HEALTH DISPARITY; HUMAN; IMMUNOLOGY; MALE; MICROCIRCULATION; MICROVASCULATURE; PATHOPHYSIOLOGY; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; TIME FACTOR; VASCULAR ENDOTHELIUM;

AUTOIMMUNE DISEASES; AUTOIMMUNITY; CARDIOVASCULAR DISEASES; COMORBIDITY; ENDOTHELIUM, VASCULAR; FEMALE; HEALTH STATUS DISPARITIES; HUMANS; MALE; MICROCIRCULATION; MICROVESSELS; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; SEX FACTORS; TIME FACTORS;

EID: 84955345774     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2015.03.044     Document Type: Article

References (69)

1. Liu Y., Dalal K., Stollenwerk B. The association between health system development and the burden of cardiovascular disease: an analysis of WHO country profiles. PLoS One 2013, 8(4):e617-618.
2. Perk J., De Backer G., Gohlke H., Graham I., Reiner Z., Verschuren M., et al. European Association for Cardiovascular Prevention & Rehabilitation (EACPR); ESC Committee for Practice Guidelines (CPG). European guidelines on cardiovascular disease prevention in clinical practice (version 2012). The fifth joint task force of the european society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur. Heart J. 2012, 33(13):1635-1701.
3. Nichols M., Townsend N., Scarborough P., et al. European Cardiovascular Disease Statistics 2012, European Heart Network and European Society of Cardiology, Brussels, Belgium.
4. Ridker P.M., Cook N.R. Statins: new American guidelines for prevention of cardiovascular disease. Lancet 2013, 382:1762-1765.
5. Yusuf S., Hawken S., Ounpuu S., et al. INTERHEART study investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004, 364:937-952.
6. Clair C., Rigotti N.A., Porneala B., Fox C.S., D'Agostino R.B., Pencina M.J., et al. Association of smoking cessation and weight change with cardiovascular disease among adults with and without diabetes. JAMA 2013, 309(10):1014-1021.
7. Ray K.K., Kastelein J.J., Boekholdt S.M., Nicholls S.J., Khaw K.T., Ballantyne C.M., et al. The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011. Eur. Heart J. 2014, 35(15):960-968.
8. Turiel M., Sarzi-Puttini P., Atzeni F., De Gennaro Colonna V., Gianturco L., Tomasoni L. Cardiovascular injury in systemic autoimmune diseases: an update. Intern. Emerg. Med. 2011, 6(Suppl. 1):99-102.
9. van den Oever I.A., van Sijl A.M., Nurmohamed M.T. Management of cardiovascular risk in patients with rheumatoid arthritis: evidence and expert opinion. Ther. Adv. Musculoskelet. Dis. 2013, 5(4):166-181.
10. Liao K.P., Soloman D.H. Traditional cardiovascular risk factors, inflammation and cardiovascular risk in rheumatoid arthritis. Rhematology (Oxford) 2013, 52(1):45-52.
11. Bairey Merz C.N., Regitz-Zagrosek V. The case for sex- and gender-specific medicine. JAMA Intern. Med. 2014, 174(8):1348-1349.
12. Handbook of Systemic Autoimmune Diseases. The Heart in Systemic Autoimmune Diseses 2004, vol. I. Elsevier.
13. Sitia S., Atzeni F., Sarzi-Puttini P., Di Bello V., Tomasoni L., Delfino L., et al. Cardiovascular involvement in systemic autoimmune diseases. Autoimmun. Rev. 2009, 8(4):281-286.
14. Hahn B.H., Grossman J., Chen W., McMahon M. The pathogenesis of atherosclerosis in autoimmune rheumatic diseases: roles of inflammation and dyslipidemia. J. Autoimmun. 2007, 28:69-75.
15. Wolfe F., Rasker J.J., Boers M., Wells G.A., Michaud K. Minimal disease activity, remission, and the long-term outcomes of rheumatoid arthritis. Arthritis Rheum. 2007, 57(6):935-942.
16. Hollan I., Meroni P.L., Ahearn J.M., Cohen Tervaert J.W., Curran S., Goodyear C.S., et al. Cardiovascular disease in autoimmune rheumatic diseases. Autoimmun. Rev. 2013, 12(10):1004-1015.
17. Wilcox J.N., Scott N.A. Potential role of the adventitia in arteritis and atherosclerosis. Int. J. Cardiol. 1996, 56:S21-S35.
18. Martínez-Valle F., Solans-Laqué R., Bosch-Gil J., Vilardell-Tarrés M. Aortic involvement in giant cell arteritis. Autoimmun. Rev. 2010, 9(7):521-524.
19. Shoenfeld Y. Infections, vaccines and autoimmunity. Lupus 2009, 18(13):1127-1128.
20. Turiel M., Gianturco L., Ricci C., Sarzi-Puttini P., Tomasoni L., De Gennaro Colonna V., et al. Silent cardiovascular involvement in patients with diffuse systemic sclerosis: a controlled cross-sectional study. Arthritis Care Res. (Hoboken) 2013, 65(2):274-280.
21. Au K., Singh M.K., Bodukam V., et al. Atherosclerosis in systemic sclerosis: a systematic review and meta-analysis. Arthritis Rheum. 2011, 63(7):2078-2090.
22. Atzeni F., Sarzi-Puttini P., Sitia S., Tomasoni L., Gianturco L., Battellino M., et al. Coronary flow reserve and asymmetric dimethylarginine levels: new measurements for identifying subclinical atherosclerosis in patients with psoriatic arthritis. J. Rheumatol. 2011, 38(8):1661-1664.
23. Shoenfeld Y., Gerli R., Doria A., Matsuura E., Cerinic M.M., Ronda N., et al. Accelerated atherosclerosis in rheumatic autoimmune diseases. Circulation 2005, 112:3337-3347.
24. Van Doornum S., Mc Coll G., Wicks I.P. Accelerated atherosclerosis: an extra-articular feature of rheumatoid arthritis. Arthritis Rheum. 2002, 46:862-873.
25. Manzi S., Meilahn E.N., Rairie J.E., Conte C.G., Medsger T.A., Jansen-McWilliams L., et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham study. Am. J. Epidemiol. 1997, 145(5):408-415.
26. Akram M.R., Handler C.E., Williams M., Carulli M.T., Andron M., Black C.M., et al. Angiographically proven coronary artery disease in scleroderma. Rheumatol. (Oxford) 2006, 45:1395-1398.
27. Turiel M., Sitia S., Atzeni F., Tomasoni L., Gianturco L., Giuffrida M., et al. The heart in rheumatoid arthritis. Autoimmun. Rev. 2010, 9(6):414-418.
28. Turiel M., Atzeni F., Tomasoni L., de Portu S., Delfino L., Bodini B.D., et al. Non-invasive assessment of coronary flow reserve and ADMA levels: a case-control study of early rheumatoid arthritis patients. Rheumatol. (Oxford) 2009, 48(7):834-839.
29. Sitia S., Tomasoni L., Atzeni F., Ambrosio G., Cordiano C., Catapano A., et al. From endothelial dysfunction to atherosclerosis. Autoimmun. Rev. 2010, 9(12):830-834.
30. Yildiz M. Arterial distensibility in chronic inflammatory rheumatic disorders. Open Cardiovasc Med. J. 2010, 4:83-88.
31. Shang Q., Tam L.S., Li E.K., et al. Increased arterial stiffness correlated with disease activity in systemic lupus erythematosus. Lupus 2008, 17(12):1096-1102.
32. De Gennaro Colonna V., Bianchi M., Pascale V., et al. Asymmetric dimethylarginine (ADMA): an endogenous inhibitor of nitric oxide synthase and a novel cardiovascular risk molecule. Med. Sci. Monit. 2009, 15(4). RA91-101.
33. Sitia S., Gianturco L., Tomasoni L., et al. Role of cardiovascular imaging in systemic autoimmune diseases. World J. Cardiol. 2010, 2(8):237-242.
34. Cortigiani L, Rigo F, Gherardi S, et al. Coronary flow reserve during dipyridamole stress echocardiography predicts mortality. JACC Cardiovasc. Imaging 2012, 5(11):1079-1085.
35. Recio-Mayoral A., Mason J.C., Kaski J.C., et al. Chronic inflammation and coronary microvascular dysfunction in patients without risk factors for coronary artery disease. Eur. Heart J. 2009, 30(15):1837-1843.
36. Kerekes G., Soltész P., Nurmohamed M.T., Gonzalez-Gay M.A., Turiel M., Végh E., et al. Validated methods for assessment of subclinical atherosclerosis in rheumatology. Nat. Rev. Rheumatol. 2012, 8(4):224-234.
37. Libby P., Ridker P.M., Hansson G.K. Progress and challenges in translating the biology of atherosclerosis. Nature 2011, 473:317-325.
38. Choy E., Sattar N. Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions. Ann. Rheum. Dis. 2009, 68:460-469.
39. Kaptoge S., Di Angelantonio E., Lowe G. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 2010, 375:132-140.
40. Libby P. Role of inflammation in atherosclerosis associated with rheumatoid arthritis. Am. J. Med. 2008, 121(Suppl. 1):S21-S31.
41. Wensley F., Gao P., Burgess S., Kaptoge S., Di Angelantonio E., Shah T., Engert J.C., Clarke R., Davey-Smith G., Nordestgaard B.G., Saleheen D., Samani N.J., Sandhu M., Anand S., Pepys M.B., Smeeth L., Whittaker J., Casas J.P., Thompson S.G., Hingorani A.D., Danesh J. C reactive protein coronary heart disease genetics collaboration (CCGC). BMJ 2011, 342:d548.
42. Miller A.M., McInnes I.B. Cytokines as therapeutic targets to reduce cardiovascular risk in chronic inflammation. Curr. Pharm. Des. 2011, 17:1-8.
43. Galkina E., Ley K. Immune and inflammatory mechanisms of atherosclerosis. Ann. Rev. Immunol. 2009, 27:165-199.
44. Matsuura E., Lopez L.R., Shoenfeld Y., Ames P.R. β2-glycoprotein I and oxidative inflammation in early atherogenesis: a progression from innate to adaptive immunity?. Autoimmun. Rev. 2012, 11:873-882.
45. Sollberger G., Strittmatter G.E., Garstkiewicz M., Sand J., Beer H.D. Caspase-1: the inflammasome and beyond. Innate Immun. 2013, 20:115-125.
46. Peters M.J., van Halm V.P., Nurmohamed M.T., Damoiseaux J., Tervaert J.W., Twisk J.W., et al. Relations between autoantibodies against oxidized low-density lipoprotein, inflammation, subclinical atherosclerosis, and cardiovascular disease in rheumatoid arthritis. J. Rheumatol. 2008, 35:1495-1499.
47. Schiele F., Chopard R. Is coronary artery disease different in women?. Presse Med. 2014, 43(7-8):796-802.
48. Schlager O., Giurgea A., Hammer A., Charwat-Resl S., Margeta C., Mueller M., et al. Impact of age and gender on microvascular function. Eur. J. Clin. Invest. 2014, 44(8):766-774.
49. Panazzolo D.G., da Silva L.H., Cyrino F.Z., Sicuro F.L., Kraemer-Aguiar L.G., Bouskela E. Gender differences in microcirculation: observation using the hamster cheek pouch. Clin. (Sao Paulo) 2013, 68(12):1537-1542.
50. Vrijenhoek J.E., Den Ruijter H.M., De Borst G.J., de Kleijn D.P., De Vries J.P., Bots M.L., et al. Sex is associated with the presence of atherosclerotic plaque hemorrhage and modifies the relation between plaque hemorrhage and cardiovascular outcome. Stroke 2013, 44(12):3318-3323.
51. Pietrzak A., Czuczwar P., Mosiewicz J., Paszkowski T., Chodorowska G., Bartosinska J., et al. Cardiovascular disease in psoriatic post-menopausal women. J. Eur. Acad. Dermatol Venereol. 2014 Jul 30, [Epub ahead of print]. 10.1111/jdv.12620.
52. Rennert G., Peterburg Y. Prevalence of selected chronic diseases in Israel. Isr. Med. Assoc. J. 2001, 3:404-408.
53. Bias W.B., Reveille J.D., Beaty T.H., Meyers D.A., Arnett F.C. Evidence that autoimmunity in man is a Mendelian dominant trait. Am. J. Hum. Genet. 1986, 39:584-602.
54. McCombe P.A., Chalk J.B., Pender M.P. Familial occurrence of multiple sclerosis with thyroid disease and systemic lupus erythematosus. J. Neurol. Sci. 1990, 97:163-171.
55. Clayton D.G. Prediction and interaction in complex disease genetics: experience in type 1 diabetes. PLoS Genet. 2009, 5:e1000540.
56. Willer C.J., Dyment D.A., Risch N.J., Sadovnick A.D., Ebers G.C. Canadian collaborative study group. Twin concordance and sibling recurrence rates in multiple sclerosis. Proc. Natl. Acad. Sci. U. S. A. 2003, 100(22):12877-12882.
57. Kuusisto H., Kaprio J., Kinnunen E., Luukkaala T., Koskenvuo M., Elovaara I. Concordance and heritability of multiple sclerosis in Finland: study on a nationwide series of twins. Eur. J. Neurol. 2008, 15(10):1106-1110.
58. Ansar Ahmed S., Penhale W.J., Talal N. Sex hormones, immune responses, and autoimmune diseases. Mechanisms of sex hormone action. Am. J. Pathol. 1985, 121:531-551.
59. Lu Q. The critical importance of epigenetics in autoimmunity. J. Autoimmun. 2013, 41:1-5.
60. Bergholm R., Leirisalo-Repo M., Vehkavaara S., Makimattila S., Taskinen M.R., Yki-Jarvinen H. Impaired responsiveness to NO in newly diagnosed patients with rheumatoid arthritis. Arterioscler. Thromb. Vasc. Biol. 2002, 22:1637-1641.
61. Foster W., Carruthers D., Lip G.Y., Blann A.D. Inflammation and microvascular and macrovascular endothelial dysfunction in rheumatoid arthritis: effect of treatment. J. Rheumatol. 2010, 37(4):711-716.
62. Yeboah J., Crouse J.R., Hsu F.C., Burke G.L., Herrington D.M. Brachial flow-mediated dilation predicts incident cardiovascular events in older adults: the cardiovascular health study. Circulation 2007, 115:2390-2397.
63. Burger D., Touyz R.M. Cellular biomarkers of endothelial health: microparticles, endothelial progenitor cells, and circulating endothelial cells. J. Am. Soc. Hypertens. 2012, 6:85-99.
64. Galarraga B., Khan F., Kumar P., Pullar T., Belch J.J. C-reactive protein: the underlying cause of microvascular dysfunction in rheumatoid arthritis. Rheumatol. (Oxford) 2008, 47:1780-1784.
65. Datta D., Ferrell W.R., Sturrock R.D., Jadhav S.T., Sattar N. Inflammatory suppression rapidly attenuates microvascular dysfunction in rheumatoid arthritis. Atherosclerosis 2007, 192:391-395.
66. Nielen M.M., Schaardenburg D., Reesink H.W., Twisk J.W., Stadt R.J., Horst-Bruinsma I.E., et al. Increased levels of C-reactive protein in serum from blood donors before the onset of rheumatoid arthritis. Arthritis Rheum. 2004, 50:2423-2427.
67. Kerekes G., Szekanecz Z., Dér H., Sándor Z., Lakos G., Muszbek L., et al. Endothelial dysfunction and atherosclerosis in rheumatoid arthritis: a multiparametric analysis using imaging techniques and laboratory markers of inflammation and autoimmunity. J. Rheumatol. 2008, 35(3):398-406.
68. Tomasoni L., Sitia S., Borghi C., Cicero A.F., Ceconi C., Cecaro F., et al. Effects of treatment strategy on endothelial function. Autoimmun. Rev. 2010, 9(12):840-844.
69. Crea F., Camici P.G., Bairey Merz C.N. Coronary microvascular dysfunction: an update. Eur. Heart J. 2014, 35(17):1101-1111.